Eliminating Monitor Overuse Trial (EMO Trial)
Trial ID or NCT#
Status
Purpose
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Official Title
Eliminating Monitor Overuse (EMO) Hybrid Effectiveness-Deimplementation Trial
Eligibility Criteria
- * Nurse or physician fluent in English and employed full-time by the hospital, affiliated practice, or affiliated university who cared for bronchiolitis patients on a unit participating in the trial during at least 5 days of the most recent bronchiolitis season* Hospital administrator fluent in English who oversaw the care of bronchiolitis on a local level (e.g. nurse manager) or a hospital level (e.g. Chief Quality and Safety Officer)
- • Under the direct supervision of study or site principal investigator(s)
- Population 1b: Hospital staff who participate in qualitative interviews
- In Aim 2, we will conduct semi-structured interviews with physicians and nurses who provide care to bronchiolitis patients in participating units at the 5 hospitals with the highest and 3 hospitals with the lowest sustainability (8 hospitals total; up to maximum of 8 interviews/hospital). Maximum anticipated enrollment 64.
- Inclusion criteria:
- * Nurses or Physicians who cared for bronchiolitis patients on a unit participating in the trial during at least 5 days of the most recent bronchiolitis season* Employed full-time by the hospital, affiliated practice, or affiliated university* Fluent in English
- Exclusion criteria:
- • No exclusion criteria
- Population 2a: Bronchiolitis patients directly observed while not receiving supplemental oxygen ("in room air," for primary trial outcome)
- Inclusion Criteria:
- * Infants and children 2 months through 23 months old* Hospitalized on non-ICU wards participating in the trial* Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)* Primary diagnosis of bronchiolitis in most recent physician progress note* Not actively receiving supplemental oxygen ("in room air")* Last documented receipt of supplemental oxygen \>1 hour prior to direct observational data collection
- Exclusion Criteria:
- * Documented apnea or cyanosis during the current illness* Extreme prematurity (\<28 weeks completed gestation)* Cardiac disease* Pulmonary hypertension* Chronic lung disease* Home oxygen requirement* Neuromuscular disease* Immunodeficiency* Cancer* Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19 / SARS-CoV-2)-related illness (known or suspected, including multisystem inflammatory syndrome in children multi-system inflammatory syndrome in children (MIS-C)
- Population 2b: Bronchiolitis patients directly observed while receiving supplemental oxygen (for underuse evaluation).
- Inclusion Criteria:
- * Infants and children 2 months through 23 months old* Hospitalized on non-ICU wards participating in the trial* Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)* Primary diagnosis of bronchiolitis in most recent physician progress note* Actively receiving ≥2 Liters/minute (2L/min) supplemental oxygen or 21% room air flow
- Exclusion Criteria:
- * Extreme prematurity (\<28 weeks completed gestation)* Cardiac disease* Pulmonary hypertension* Chronic lung disease* Home oxygen requirement* Neuromuscular disease* Immunodeficiency* Cancer* Severe Acute Respiratory Syndrome Coronavirus 2 \[Covid-19 / SARS-CoV-2 (known or suspected)\]
- Population 3: Parents or guardians of bronchiolitis patients who participate in qualitative interviews.
- Inclusion Criteria:
- * Their child was hospitalized for bronchiolitis on a unit participating in the trial during the most recent bronchiolitis season* Their child was found to be in room air during Aim 1 data collection* Fluent in English
- Exclusion criteria:
- • They are an employee of the hospital or a hospital volunteer
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Alan Schroeder
View on ClinicalTrials.gov